Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Roche RHHBY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted ...

Baseline tumor-infiltrating lymphocytes and positive nodes can help identify women with TMBC at high risk for relapse despite ...

VTV.vn - Pfizer Vietnam, in collaboration with Vietnam Cancer Association and Vietnam Cancer Immunotherapy Association, ...

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

Health experts discuss advanced biologic therapies in breast cancer treatment at a recent symposium in Hà Nội.

The breast cancer treatment market is rapidly growing, driven by advances in technology, personalized therapies and early diagnosis efforts.

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.